| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $15.6M | — | -19.7% |
| SG&A Expense | $5.2M | — | -1.9% |
| Operating Income | -$20.8M | — | +15.9% |
| Net Income | $9.2M | — | +138.8% |
| EPS (Basic) | $0.06 | — | +112.2% |
| EPS (Diluted) | $0.06 | — | +112.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $63.2M | -22.5% | +50.0% |
| Current Assets | $65.9M | -24.7% | +40.1% |
| Total Assets | $99.4M | -18.1% | +19.7% |
| Current Liabilities | $15.4M | -15.9% | -18.0% |
| Total Liabilities | $78.0M | -30.3% | +1.8% |
| Stockholders' Equity | $21.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$22.5M | — | +10.4% |
| Capital Expenditures | $448K | — | +0.0% |
| Investing Cash Flow | -$448K | — | +0.0% |
| Financing Cash Flow | $4.1M | — | +2300.6% |
| Free Cash Flow | -$22.9M | — | +10.2% |
| +235.3% |